124 related articles for article (PubMed ID: 7632640)
1. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
Smith RN; Studd JW; Zamblera D; Holland EF
Br J Obstet Gynaecol; 1995 Jun; 102(6):475-84. PubMed ID: 7632640
[TBL] [Abstract][Full Text] [Related]
2. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
5. A simple, inexpensive and effective artificial cycle with exogenous transdermal oestradiol and vaginal progesterone for the transfer of cryopreserved pronucleated human oocytes in women with normal cycles.
Bals-Pratsch M; Al-Hasani S; Schöpper B; Diedrich C; Hoepfner AS; Weiss J; Küpker W; Felberbaum R; Ortmann O; Bauer O; Diedrich K
Hum Reprod; 1999 Sep; 14 Suppl 1():222-30. PubMed ID: 10573036
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
9. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
10. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone.
Watson NR; Studd JW; Savvas M; Garnett T; Baber RJ
Lancet; 1989 Sep; 2(8665):730-2. PubMed ID: 2570971
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.
Hänggi W; Lippuner K; Jaeger P; Birkhäuser MH; Horber FF
Clin Endocrinol (Oxf); 1998 Jun; 48(6):691-9. PubMed ID: 9713556
[TBL] [Abstract][Full Text] [Related]
13. [Use of estrogens in skin patches in treatment of pre-menstrual syndrome].
Liber Z; Spiewankiewicz B; Stelmachów J
Pol Tyg Lek; 1992 Nov 2-9; 47(44-45):1018-20. PubMed ID: 1305712
[TBL] [Abstract][Full Text] [Related]
14. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
[TBL] [Abstract][Full Text] [Related]
15. A direct comparison of women's perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age.
Mittal M; Panay N; Supramaniam PR; Savvas M; Cardozo L; Hamoda H
Post Reprod Health; 2020 Dec; 26(4):210-219. PubMed ID: 33045913
[TBL] [Abstract][Full Text] [Related]
16. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation.
Kekkonen R; Croxatto HB; Lähteenmäki P; Salvatierra AM; Tuominen J
Hum Reprod; 1995 Feb; 10(2):287-92. PubMed ID: 7769050
[TBL] [Abstract][Full Text] [Related]
17. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
Mezrow G; Shoupe D; Spicer D; Lobo R; Leung B; Pike M
Fertil Steril; 1994 Nov; 62(5):932-7. PubMed ID: 7926137
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of oestradiol from the Alora (0.1 mg/day) oestradiol matrix transdermal delivery system compared with Estraderm (0.1 mg/day).
Bowen A; John VA; Ramirez ME; Good WR
J Obstet Gynaecol; 1998 Nov; 18(6):575-80. PubMed ID: 15512184
[TBL] [Abstract][Full Text] [Related]
19. Buserelin in premenstrual syndrome.
Hussain SY; Massil JH; Matta WH; Shaw RW; O'Brien PM
Gynecol Endocrinol; 1992 Mar; 6(1):57-64. PubMed ID: 1580169
[TBL] [Abstract][Full Text] [Related]
20. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women.
Mattsson LA; Samsioe G; von Schoultz B; Uvebrant M; Wiklund I
Br J Obstet Gynaecol; 1993 May; 100(5):450-3. PubMed ID: 8518245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
